A companion diagnostic is a test specifically validated and, in most cases, FDA-approved alongside a particular targeted therapy — the drug and the test are developed and reviewed together, with the test result determining whether a given patient is eligible for that specific treatment. This co-development model has become the standard regulatory pathway for modern targeted cancer therapies, and understanding how it works clarifies both its clinical value and some of the practical friction points patients and oncologists navigate.
Why Drugs and Tests Are Developed Together
Targeted cancer therapies work by interfering with a specific molecular pathway that drives a subset of tumors — a drug targeting EGFR mutations, for instance, only benefits patients whose tumor actually carries that mutation, and may be ineffective or even inappropriate for patients without it. Clinical trials for these drugs are conducted specifically in biomarker-positive patients identified through the companion diagnostic, which means the FDA approval itself is contingent on the biomarker-selected population — the drug's proven safety and efficacy data does not extend to biomarker-negative patients, making the companion diagnostic an integral, not optional, part of appropriate prescribing.
Single-Gene Tests Versus Comprehensive Genomic Panels
Early companion diagnostics tested for a single specific mutation relevant to one drug, but as the number of targetable mutations across cancer types has grown, comprehensive genomic profiling panels — testing dozens to hundreds of genes simultaneously from a single tumor sample — have become increasingly common, allowing oncologists to identify multiple potentially actionable mutations from one test rather than ordering sequential single-gene tests. Several comprehensive panels have themselves received FDA approval as companion diagnostics for multiple different targeted therapies simultaneously, reflecting this shift toward broader, more efficient testing strategies.
Tissue Availability Is a Persistent Practical Barrier
Companion diagnostic testing typically requires an adequate tumor tissue sample, usually obtained through the original diagnostic biopsy — but tissue quantity and quality can be insufficient for comprehensive testing, particularly from small needle biopsies of hard-to-reach tumors, sometimes requiring a repeat biopsy procedure specifically to obtain adequate tissue for genomic testing, adding time, cost, and procedural risk to the diagnostic process. This tissue adequacy challenge has been a significant driver behind the development of liquid biopsy alternatives.
Turnaround Time Affects Real-World Treatment Decisions
Comprehensive genomic testing can take one to several weeks to return results, a delay that creates genuine clinical tension for patients with aggressive cancers where oncologists may feel pressure to begin treatment before results are available, potentially starting a less targeted approach and then adjusting once genomic results return. Faster-turnaround, more focused test panels have been developed specifically to address this tension for the most clinically urgent situations, trading some breadth of genetic coverage for speed.
Insurance Coverage and Access Variation
Coverage for companion diagnostic and comprehensive genomic testing has expanded considerably as evidence supporting these tests' clinical utility has grown, with Medicare and most major payers now covering FDA-approved companion diagnostics tied to an approved therapy. Coverage for broader genomic panels testing beyond a single approved companion diagnostic indication remains more variable across payers, an access gap that has been a recurring focus of oncology advocacy given the value of comprehensive testing in identifying clinical trial eligibility beyond currently approved therapies alone.
Conclusion
Companion diagnostics represent the regulatory and clinical backbone connecting precision oncology's targeted therapies to the specific patients who will actually benefit from them, though tissue adequacy, turnaround time, and coverage variation for comprehensive panels remain real practical friction points. Oncology programs rely on dependable lab supplies and diagnostic equipment to support the biopsy and testing workflow this model depends on.
